Published: Thu, November 22, 2018
Medicine | By Tracy Klein

Will Peanut Treatment Guard Against Peanut Allergy?

Will Peanut Treatment Guard Against Peanut Allergy?

With the study's findings now published to The New England Journal of Medicine, AR101 will be submitted to the US Food and Drug Administration (FDA) for a Biologics License Application by the end of 2018, and is expected to be fast-tracked on the FDA Breakthrough Therapy Designation for patients from ages four to 17 years with a peanut allergy.

"This is not a quick fix, and it doesn't mean people with peanut allergy will be able to eat peanuts whenever they want", says allergist Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author.

Professor George du Toit, paediatric allergy consultant at Evelina London and the study's chief investigator, said: 'Peanut allergy is extremely hard to manage for children and their families, as they have to follow a strict peanut-free diet. The goal was to build up a tolerance so a person wouldn't risk a severe or potentially deadly allergic reaction if accidentally exposed to a peanut.

The trial found that participants not normally able to tolerate exposure to even a tenth of a single peanut could eventually cope with two whole peanuts.

There are now no approved treatments that prevent or reduce the symptoms of any type of food allergy.

Patients suffering from a peanut allergy were given the oral drug containing a daily dose of peanut protein.

After one year of treatment with a newly invented drug by Immune Therapeutics, says about 70% of children and teenagers suffering from peanut allergies were able to accept two peanuts or equivalent. The kids, who initially had allergic reactions to peanut protein in amounts no larger than 100mg, were given increasing doses of AR101 over six months, followed by six months of a "maintenance" dose.

The medically supervised trial at Cork University Hospital offered Eoghan the chance of living a life free from the threat of his allergy.

'We were quite shocked how you could find traces of peanuts and nuts in all sorts of food, particularly foods that are childhood foods - cakes, biscuits, ice-creams - and that's what was stressful. "The impact on our family life was huge". The treatment process required a significant commitment; AR101 had to be administered every day, and after each dose, children were required to rest for two hours.

People rarely outgrow the allergy which is the most common cause of food allergy deaths.

Researchers in 10 countries across North America and Europe conducted the trial, known as the Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization trial, or PALISADE, for short.

Like this: